NCT02123290View on ClinicalTrials.gov

DSM265 Phase IIa Investigation Treating Plasmodium Falciparum or Vivax

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions
Plasmodium Falciparum MalariaPlasmodium Vivax Malaria
Interventions
DRUG

DSM265 400mg

DRUG

DSM265 xmg

Dose of DSM265 to be determined based on the results of the first cohort

DRUG

DSM265 ymg

Dose of DSM265 to be determined based on the results of the second cohort

Trial Locations (1)

Unknown

Clínica de la Asociación Civil Selva Amazónica, Iquitos

All Listed Sponsors
collaborator

Asociacion Civil Selva Amazonica

OTHER

lead

Medicines for Malaria Venture

OTHER

NCT02123290 - DSM265 Phase IIa Investigation Treating Plasmodium Falciparum or Vivax | Biotech Hunter | Biotech Hunter